255 related articles for article (PubMed ID: 14749510)
1. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Seckl JR; Morton NM; Chapman KE; Walker BR
Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
[TBL] [Abstract][Full Text] [Related]
2. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
6. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
8. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
9. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
10. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.
Masuzaki H; Yamamoto H; Kenyon CJ; Elmquist JK; Morton NM; Paterson JM; Shinyama H; Sharp MG; Fleming S; Mullins JJ; Seckl JR; Flier JS
J Clin Invest; 2003 Jul; 112(1):83-90. PubMed ID: 12840062
[TBL] [Abstract][Full Text] [Related]
11. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
Seckl JR; Walker BR
Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
[TBL] [Abstract][Full Text] [Related]
12. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Prasad Sakamuri SS; Sukapaka M; Prathipati VK; Nemani H; Putcha UK; Pothana S; Koppala SR; Ponday LR; Acharya V; Veetill GN; Ayyalasomayajula V
PLoS One; 2012; 7(12):e50216. PubMed ID: 23284633
[TBL] [Abstract][Full Text] [Related]
13. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Morgan SA; Tomlinson JW
Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
[TBL] [Abstract][Full Text] [Related]
14. 11β-HSD1 contributes to age-related metabolic decline in male mice.
Morgan SA; Gathercole LL; Hassan-Smith ZK; Tomlinson J; Stewart PM; Lavery GG
J Endocrinol; 2022 Dec; 255(3):117-129. PubMed ID: 36205523
[TBL] [Abstract][Full Text] [Related]
15. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.
Chapman K; Holmes M; Seckl J
Physiol Rev; 2013 Jul; 93(3):1139-206. PubMed ID: 23899562
[TBL] [Abstract][Full Text] [Related]
16. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Oppermann U
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
[TBL] [Abstract][Full Text] [Related]
17. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
[TBL] [Abstract][Full Text] [Related]
18. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
19. Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.
Espíndola-Antunes D; Kater CE
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1397-403. PubMed ID: 18209879
[TBL] [Abstract][Full Text] [Related]
20. Dietary manipulation reveals an unexpected inverse relationship between fat mass and adipose 11β-hydroxysteroid dehydrogenase type 1.
Man TY; Michailidou Z; Gokcel A; Ramage L; Chapman KE; Kenyon CJ; Seckl JR; Morton NM
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1076-84. PubMed ID: 21406612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
